Log In
Print this Print this

LongSeven, NecLip-rFVIIa

  Manage Alerts
Collapse Summary General Information
Company Recoly N.V.
DescriptionRecombinant Factor VIIa (rFVIIa) formulated with NecLip liposomes
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I/II
Standard IndicationHemophilia
Indication DetailsTreat bleeding in hemophilia patients
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today